has just approved the drug Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) as treatment for people with ...

We read with interest the article by Marie Lund and colleagues published in The Lancet Oncology investigating the association ...

"What's important is that these drugs significantly reduce late recurrences," says Isaacs. But she notes that researchers still don't know which strategy works best: taking an aromatase inhibitor ...

Do innovator drugs work better than generic ... Ask the Pharmacists, November 2010 Can the Duration of Aromatase Inhibitor Therapy Exceed 5 Years? Does extended-duration aromatase inhibitor ...

Novartis’ Kisqali (ribociclib) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat a ...

Burnett-Bowie et al. investigated the efficacy and safety of the synthetic aromatase inhibitor anastrozole to treat hypogonadism in aging men. The study enrolled 88 men (60 years or older ...

We played a leading role in clinical trials that demonstrated the effectiveness of aromatase inhibitors in breast cancer, and in identifying and validating biomarkers to determine who could benefit ...

The regulator approved the indication based on data showing Kisqali with an aromatase inhibitor improved invasive disease-free survival versus just an aromatase inhibitor.

in combination with an aromatase inhibitor or fulvestrant. The drug can be used in women who have not received endocrine therapy, or women who have received this form of therapy. Already approved ...

when the SMC gave the green light for restricted prescribing of the drug in first-line HR+/HER2- breast cancer in combination with aromatase inhibitor drugs. Both are also trying to get the okay ...

Treatment with the aromatase inhibitor anastrozole decreased the ... (New York Times) Disparities in access to novel anti-obesity drugs could be made worse if the medications are denied to people ...

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.